Recent share performance and valuation context
Addus HomeCare (ADUS) has been under pressure recently, with the stock down about 9% over the past month and 13% over the past 3 months, leaving it roughly 16% lower year to date.
Despite that pullback, the company reports annual revenue of US$1.45b and net income of US$99.75m. Its current share price of US$89.70 implies a market value of about US$1.62b.
See our latest analysis for Addus HomeCare.
The recent 1-day share price gain of 1.37% only partially offsets a wider slide, with the 30-day share price return down 8.88% and the 1-year total shareholder return declining 20.03%. This suggests fading momentum despite the company’s revenue and earnings profile.
If recent weakness in Addus HomeCare has you reassessing your watchlist, it could be a useful moment to scan for other healthcare opportunities, including 40 healthcare AI stocks
With the stock down over the past year yet trading on financials that include US$1.45b in revenue and US$99.75m in net income, you have to ask: is Addus HomeCare undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 18.5% Undervalued
Compared with the last close at $89.70, the most widely followed narrative pegs Addus HomeCare’s fair value at $110.03, framing the recent share price weakness in a very different light.
The looming threat of significant government healthcare spending cuts to address federal budget deficits could reduce funding for Medicaid and Medicare programs, which are critical revenue streams for Addus HomeCare. This would directly pressure revenue and earnings, especially as provisions of the reconciliation bill begin to impact state budgets in 2028.
Want to see what underpins that valuation gap? The narrative rests on measured revenue growth, firmer margins and a future earnings multiple that has to do some heavy lifting.
Result: Fair Value of $110.03 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still factors that could shift this picture, including steady reimbursement support in key states and an earnings uplift from recent acquisitions.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Next Steps
Given the mixed tone around valuation and risks, it helps to move quickly and ground your own view in the underlying data. A good starting point is the 5 key rewards.
Looking for more investment ideas?
If you stop here, you could miss stocks that better fit your goals. Spend a few minutes with these focused lists and upgrade your opportunity set today.
- Target potential bargains with strong fundamentals by scanning companies on the 47 high quality undervalued stocks.
- Strengthen your income focus by reviewing high-yield opportunities highlighted in the 10 dividend fortresses.
- Prioritise resilience by zeroing in on stocks featured in the 65 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com